Brainstorm Cell Therapeutics Files 8-K on Financials
Ticker: BCLI · Form: 8-K · Filed: Apr 1, 2024 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, filing
TL;DR
Brainstorm Cell Therapeutics filed an 8-K on April 1, 2024, detailing financial condition and operations.
AI Summary
On April 1, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided text, but the filing indicates a report on these aspects.
Why It Matters
This 8-K filing provides an update on Brainstorm Cell Therapeutics' financial condition and operations, which is crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting financial condition and operations, without immediate news of significant events.
Key Players & Entities
- BRAINSTORM CELL THERAPEUTICS INC. (company) — Registrant
- April 1, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36641 (identifier) — SEC File Number
FAQ
What specific financial results are being reported in this 8-K filing?
The filing indicates it concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the provided text does not detail specific financial figures.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated April 1, 2024.
What is the state of incorporation for Brainstorm Cell Therapeutics Inc.?
Brainstorm Cell Therapeutics Inc. is incorporated in Delaware.
What is the SEC file number for Brainstorm Cell Therapeutics Inc.?
The SEC file number for Brainstorm Cell Therapeutics Inc. is 001-36641.
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the company's results of operations and financial condition, as well as to file financial statements and exhibits.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-04-01 08:15:33
Key Financial Figures
- $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L
Filing Documents
- tm2410297d1_8k.htm (8-K) — 24KB
- tm2410297d1_ex99-1.htm (EX-99.1) — 98KB
- tm2410297d1_ex99-1img001.jpg (GRAPHIC) — 41KB
- 0001104659-24-041549.txt ( ) — 360KB
- bcli-20240401.xsd (EX-101.SCH) — 3KB
- bcli-20240401_lab.xml (EX-101.LAB) — 33KB
- bcli-20240401_pre.xml (EX-101.PRE) — 22KB
- tm2410297d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial
Item 2.02. Results of Operations and Financial Condition. On April 1, 2024, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2023. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued by Brainstorm Cell Therapeutics Inc. on April 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: April 1, 2024 By: /s/ Chaim Lebovits Chaim Lebovits President and Co-Chief Executive Officer